AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31996267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ojeok-san plus Saengmaek-san (5.76 g, three times per day for 6 weeks)
Number of subjects: 30
Study 31996267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times per day for 6 weeks)
Number of subjects: 30
Study 31996267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ojeok-san plus Saengmaek-san
Number of subjects: 30
Study 31996267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31437539 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary integrated care (gastroenterologist, gut-hypnotherapist, psychiatrist, behavioral therapist, dietician)
Number of subjects: 0
Study 31437539 — intervention group
Group type: COMPARATOR
Intervention: Standard care (gastroenterologist or colorectal surgeon)
Number of subjects: 0
Study 31437539 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary integrated care
Number of subjects: 0
Study 31437539 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 28105731 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg/d)
Number of subjects: 32
Study 25770176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU weekly (n=36)
Number of subjects: 105
Study 25770176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU monthly (n=33)
Number of subjects: 105
Study 25770176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=36)
Number of subjects: 105
Study 25770176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU weekly
Number of subjects: 105
Study 25770176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU monthly
Number of subjects: 105
Study 25770176 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study 25770176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol-treated participants
Number of subjects: 105
Study 23209111 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized breastfeeding peer counseling (SBFPC)
Number of subjects: 206
Study 23209111 — intervention group
Group type: COMPARATOR
Intervention: Standard care (controls)
Number of subjects: 206
Study 21596046 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 0
Study 21596046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19839212 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions (surgery)
Number of subjects: 0
Study 19839212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic studies
Number of subjects: 0
Study 19839212 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicentre clinical studies
Number of subjects: 0
Study 19839212 — intervention group
Group type: EXPERIMENTAL
Intervention: Good clinical and comparative health care effectiveness research
Number of subjects: 0
Study 22269571 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME For Life(®) ‐ PFL
Number of subjects: 522
Study 22269571 — intervention group
Group type: COMPARATOR
Intervention: Intervention as usual (IAU)
Number of subjects: 522
Study 22269571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PFL and IAU)
Number of subjects: 522
Study 15955039 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) performed on day 2
Number of subjects: 79
Study 15955039 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) performed on day 3
Number of subjects: 79
Study 15955039 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) performed on day 4
Number of subjects: 79
Study 12601664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand splinting in the functional position (10 degrees - 30 degrees wrist extension) for a maximum of 12 hours each night for 4 weeks.
Number of subjects: 28
Study 12601664 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy-motor training for upper-limb use and upper-limb stretches (5 days a week).
Number of subjects: 28
Study 9447855 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1.106 KIU bolus followed by 5 x 10(5) KIU/h infusion)
Number of subjects: 23
Study 9447855 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 23
Study 9447855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 23
Study 9447855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7560990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 30000
Study 7560990 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 30000
Study 7560990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study 2757771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychosensorial stimulation at home by mothers, trained and inspected by nurses.
Number of subjects: 96
Study 2757771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive psychosensorial stimulation).
Number of subjects: 96
Study 589308 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 243
Study 589308 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 243
Study 589308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 11978259 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain oat-based cereals
Number of subjects: 88
Study 11978259 — intervention group
Group type: COMPARATOR
Intervention: Refined grain wheat-based cereals
Number of subjects: 88
Study 31957965 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dual antiplatelet therapy (DAPT) beyond 12 months
Number of subjects: 4197
Study 31957965 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard DAPT for 12 months)
Number of subjects: 4197
Study 31957965 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended DAPT
Number of subjects: 4197
Study 30020983 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM training (attending away from pain)
Number of subjects: 58
Study 30020983 — intervention group
Group type: COMPARATOR
Intervention: Sham training (no training direction)
Number of subjects: 58
Study 26492058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Steroid Administration
Number of subjects: 549
Study 26492058 — intervention group
Group type: COMPARATOR
Intervention: Non-recipients (Control)
Number of subjects: 549
Study 24486732 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-directed e-health strategy for cardiovascular risk management
Number of subjects: 2000
Study 24486732 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2000
Study 22665903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d orally
Number of subjects: 331
Study 22665903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 19650804 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 13 mg
Number of subjects: 64
Study 19650804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg plus sufentanil 5 microg
Number of subjects: 64
Study 19095139 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins plus ezetimibe
Number of subjects: 0
Study 19095139 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins alone
Number of subjects: 0
Study 19095139 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (target LDL-C <= 100 mg/dl)
Number of subjects: 0
Study 15741225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel (GD)
Number of subjects: 311
Study 15741225 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-vinorelbine (CV)
Number of subjects: 311
Study 12032392 — intervention group
Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 39
Study 12032392 — intervention group
Group type: EXPERIMENTAL
Intervention: loading dose clopidogrel (450 mg)
Number of subjects: 39
Study 12032392 — intervention group
Group type: COMPARATOR
Intervention: ticlopidine post-stenting
Number of subjects: 39
Study 12032392 — intervention group
Group type: COMPARATOR
Intervention: aspirin + ticlopidine post-stenting
Number of subjects: 39
Study 12032392 — intervention group
Group type: COMPARATOR
Intervention: aspirin + abciximab + ticlopidine post-stenting
Number of subjects: 39
Study 10073848 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization after first acute myocardial infarction
Number of subjects: 817
Study 10073848 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (no revascularization)
Number of subjects: 817
Study 7888514 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (4-6 mg.kg‐1)
Number of subjects: 36
Study 7888514 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2-2.5 mg.kg‐1)
Number of subjects: 36
Study 2671808 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunoxaprofen
Number of subjects: 0
Study 2671808 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 0
Study 96062 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron-telecobalt therapy
Number of subjects: 265
Study 96062 — intervention group
Group type: COMPARATOR
Intervention: Telecobalt therapy
Number of subjects: 265
Study 31242350 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace injuries in micro and small enterprises (MSE)
Number of subjects: 290
Study 28456395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-depleting filter
Number of subjects: 30
Study 28456395 — intervention group
Group type: COMPARATOR
Intervention: Control group (without lipid-depleting filter)
Number of subjects: 30
Study 25410653 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 83
Study 25410653 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 83
Study 25410653 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 83
Study 23142194 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 23142194 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 23142194 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21050694 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multi-professional educational programme
Number of subjects: 128
Study 21050694 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving information according to hospital routines
Number of subjects: 128
Study 19496838 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gluco-oligosaccharide and collagen tripeptide F
Number of subjects: 40
Study 19496838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16446331 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy (ERT)
Number of subjects: 1236
Study 16446331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1236
Study 14505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum F toxoid vaccine (Bot F) administered 1-3 times
Number of subjects: 144
Study 14505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum F toxoid vaccine (Bot F) administered 3 times over 28-42 days
Number of subjects: 144
Study 14505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of Botulinum F toxoid vaccine (Bot F) administered at 1 year
Number of subjects: 144
Study 14505916 — intervention group
Group type: COMPARATOR
Intervention: Licensed, alum-adsorbed hepatitis B vaccine (Engerix-B)
Number of subjects: 144
Study 10806283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0
Study 10806283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study 10806283 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 0
Study 10806283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function (fourth measure with greatest processing load)
Number of subjects: 0
Study 8632929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (4 mL, 2 mg)
Number of subjects: 50
Study 8632929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mL of 0.9% saline solution)
Number of subjects: 50
Study 1483494 — intervention group
Group type: EXPERIMENTAL
Intervention: +/- Nicardipine 50 mg b.d.
Number of subjects: 19
Study 1483494 — intervention group
Group type: COMPARATOR
Intervention: Slow release nifedipine 20 mg b.d.
Number of subjects: 19
Study 2416663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (0.5; 1.0 or 1.3 IDU X kg‐1 X h‐1) plus secretin (0.5 CU X kg‐1 X h‐1)
Number of subjects: 20
Study 2416663 — intervention group
Group type: COMPARATOR
Intervention: Cholecystokinin (0; 0.5; 1.0 or 1.3 IDU X kg‐1 X h‐1) plus secretin (0.5 CU X kg‐1 X h‐1)
Number of subjects: 20
Study 31508899 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/relebactam 500/250 mg administered as a 30-minute intravenous infusion four times daily.
Number of subjects: 0
Study 31508899 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function estimated by creatinine clearance.
Number of subjects: 0
Study 31508899 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and health status.
Number of subjects: 0
Study 31508899 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations for joint target attainment.
Number of subjects: 0
Study 29215518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Molecular-Weight Heparin + Aspirin
Number of subjects: 185
Study 29215518 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 185
Study 26956476 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 82
Study 26956476 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic debridement (AD)
Number of subjects: 82
Study 24657003 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus trastuzumab
Number of subjects: 235
Study 24657003 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 235
Study 24657003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological complete response with trastuzumab
Number of subjects: 235
Study 24657003 — intervention group
Group type: COMPARATOR
Intervention: Pathological complete response with chemotherapy alone
Number of subjects: 235
Study 24657003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular adverse events
Number of subjects: 235
Study 22907422 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO + sulindac
Number of subjects: 267
Study 22907422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 20814327 — intervention group
Group type: EXPERIMENTAL
Intervention: Full adherence (204 patients, 33.7%)
Number of subjects: 605
Study 20814327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence (287 patients, 47.4%)
Number of subjects: 605
Study 20814327 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent medication refusal (114 patients, 18.8%)
Number of subjects: 605
Study 18004659 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive school-based preventive intervention
Number of subjects: 0
Study 18004659 — intervention group
Group type: EXPERIMENTAL
Intervention: Less acculturated families
Number of subjects: 0
Study 18004659 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language families with less acculturated adolescents
Number of subjects: 0
Study 18004659 — intervention group
Group type: EXPERIMENTAL
Intervention: Family language and target child's familism values
Number of subjects: 0
Study 18004659 — intervention group
Group type: EXPERIMENTAL
Intervention: Family single- vs. dual-parent status and primary parent's work hours
Number of subjects: 0
Study 16087788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered on awakening
Number of subjects: 257
Study 16087788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered at bedtime
Number of subjects: 257
Study 16087788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered at bedtime in non-dipper patients
Number of subjects: 257
Study 16087788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered at bedtime in dipper patients
Number of subjects: 257
Study 12118869 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfaces with large pixel-to-pixel luminance variations
Number of subjects: 8
Study 12118869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical line patterns
Number of subjects: 8
Study 12118869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical stimuli
Number of subjects: 8
Study 10383561 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated aspirin 162.5 mg
Number of subjects: 104
Study 10383561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin EC 150 mg
Number of subjects: 104
Study 10383561 — intervention group
Group type: COMPARATOR
Intervention: Aspirin EC 75 mg
Number of subjects: 104
Study 8533996 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan-prednisone and interferon
Number of subjects: 583
Study 8533996 — intervention group
Group type: COMPARATOR
Intervention: melphalan-prednisone
Number of subjects: 583
Study 1858154 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 151
Study 1858154 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug therapy
Number of subjects: 151
Study 6342657 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 30
Study 6342657 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ECV)
Number of subjects: 30
Study 29474093 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 154
Study 29474093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 154
Study 29145839 — intervention group
Group type: EXPERIMENTAL
Intervention: TG-C (intraarticular 3:1 mixture of non-transduced allogeneic human chondrocytes and TG-C)
Number of subjects: 86
Study 29145839 — intervention group
Group type: EXPERIMENTAL
Intervention: TG-C
Number of subjects: 86
Study 29145839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 26575258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks (HCV genotype 2)
Number of subjects: 543
Study 26575258 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-ribavirin for 12 weeks (HCV genotype 2)
Number of subjects: 543
Study 26575258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks (HCV genotype 3)
Number of subjects: 543
Study 26575258 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-ribavirin for 24 weeks (HCV genotype 3)
Number of subjects: 543
Study 24125107 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa
Number of subjects: 56
Study 21930046 — intervention group
Group type: EXPERIMENTAL
Intervention: epi‐LASIK flap-on
Number of subjects: 40
Study 21930046 — intervention group
Group type: EXPERIMENTAL
Intervention: epi‐LASIK flap-off
Number of subjects: 40
Study 21930046 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK flap-on
Number of subjects: 40
Study 21930046 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK flap-off
Number of subjects: 40
Study 21930046 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 40
Study 18760142 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (PCI with stents)
Number of subjects: 1235
Study 18760142 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-guided management
Number of subjects: 1235
Study 16997664 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg daily)
Number of subjects: 5269
Study 16997664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5269
Study 15638069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo special extract EGb 761
Number of subjects: 0
Study 10860192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (diastolic blood pressure goal of 75 mmHg)
Number of subjects: 470
Study 10860192 — intervention group
Group type: COMPARATOR
Intervention: Moderate blood pressure control (diastolic blood pressure goal of 80‐89 mmHg)
Number of subjects: 470
Study 10860192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (nisoldipine or enalapril)
Number of subjects: 470
Study 10860192 — intervention group
Group type: COMPARATOR
Intervention: Moderate therapy (nisoldipine or enalapril)
Number of subjects: 470
Study 10860192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 470
Study 10860192 — intervention group
Group type: COMPARATOR
Intervention: Moderate blood pressure control
Number of subjects: 470
Study 10860192 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 470
Study 10860192 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 470
Study 9217378 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg administered 2 hours before operation (group S)
Number of subjects: 10
Study 9217378 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment (group C)
Number of subjects: 10
Study 8380242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 93
Study 8380242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 3542493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 33
Study 3403101 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1-g doses twice daily for 45 days)
Number of subjects: 38
Study 3403101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29402258 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based play-assisted stimulation for 1 hour during weekly home visits over 6 months
Number of subjects: 78
Study 29402258 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based play-assisted stimulation
Number of subjects: 78
Study 29402258 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic services only)
Number of subjects: 78